Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • high-dose chemotherapy  (5)
  • Autologous peripheral blood stem cell transplantation  (2)
  • Interleukin-2  (2)
  • Leukämie  (2)
  • 1
    Electronic Resource
    Electronic Resource
    Minimal residual disease in autologous hematopoietic harvests from breast cancer patients (1998)
    Springer
    Annals of oncology 9 (1998), S. 821-826 
    Details
    ISSN: 1569-8041
    Keywords: breast cancer ; high-dose chemotherapy ; minimal residual disease ; stem cell transplantation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The increasing use of high-dose chemotherapy with autologous hematopoietic transplantation for the treatment of solid malignancies has raised concern about the role of tumor cells contaminating the grafts. Minimal residual disease (MRD) in autologous grafts has became a dynamic and intensively studied field in oncology. This review discusses the current status of MRD in breast cancer autografts and presents existing data on detection methodology, clinical relevance, biologic characteristics and purging techniques.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008344708061
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    High-dose chemotherapy and autologous hematopoieticstem cell transplantation in patients with second primary malignancies (1997)
    Springer
    Hematology and cell therapy 39 (1997), S. 79-83 
    Details
    ISSN: 1279-8509
    Keywords: Autologous bone marrow transplantation ; Autologous peripheral blood stem cell transplantation ; High-dose chemotherapy ; Second primary neoplasms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We treated 500 patients with high-dose chemotherapy and autologous bone marrow or autologous peripheral blood stem cell transplantation. Treated conditions included leukemia, lymphoma, breast cancer, lung cancer, germ-cell carcinoma, and other solid tumors. 10/500 (2%) of patients were treated for a second malignancy diagnosed 12 months to 25 years after their initial neoplasm. Four of these ten patients are in complete remission (CR) of both malignancies at a median follow-up of 29+ months after high-dose chemotherapy and autotransplantation. None of these patients would have been eligible for high-dose chemotherapy and autotransplantation by conventional selection criteria which usually exclude patients with a history of prior malignancies. Conclusion. Conventional exclusion criteria for high-dose chemotherapy and autotransplantation may not adequately reflect the prognosis of patients with second or secondary malignancies treated with this therapeutic modality. High-dose chemotherapy and autologous hematopoietic stem cell transplantation may be of true benfit in selected cases of secondary malignancies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s00282-997-0079-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer (1997)
    Springer
    Annals of oncology 8 (1997), S. 57-64 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; hematopoietic growth-factor support ; high-dose chemotherapy ; non-small-cell lung cancer ; peripheral blood stem cell transplantation ; treatment toxicity and mortality
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: We conducted a phase I/II trial to assess the feasibilityand activity of combination chemotherapy with etoposide, ifosfamide,cisplatin, and epirubicin in limited-stage (LS, stage I–IIIB) andextensive-stage (ES, stage IV) non-small-cell lung cancer (NSCLC). End-pointswere treatment-related morbidity and mortality, response rate, duration ofresponse, and survival. Patients and methods: Chemotherapy followed by granulocytecolony-stimulating factor was given at a dose of etoposide (500mg/m2), ifosfamide (4000 mg/m2), cisplatin (50mg/m2), and epirubicin (50 mg/m2) (VIP-E) to107 patients with NSCLC. Twenty-five patients with qualifying responsesproceeded to high-dose chemotherapy with autologous peripheral blood stem celltransplantation after etoposide (1500 mg/m2), ifosfamide(12,000 mg/m2), carboplatin (750 mg/m2) andepirubicin (150 mg/m2) (VIC-E) conditioning. Results of conventional-dose VIP-E: 35 of 102 (34%) evaluablepatients responded (2 CR's, 33 PR's), 33/102 patients (33%) showed nochange (NC); the remainder of patients progressed with therapy (PD). Objectiveresponse rate was 68% (4% CR, 64% PR) in LS-NSCLC and23% (1.4% CR, 21.4% PR) in ES-NSCLC. Median duration ofsurvival was 13 months in LS-NSCLC and 5.5 months in ES-NSCLC. Two-yearsurvival was 26% in LS and 2% in ES-NSCLC. Results of high-dose VIC-E: 23 of 24 evaluable patients improved ormaintained prior responses (92%), 1 patient showed NC. Treatmentmortality was 4%. Median duration of survival was 17 months in LS-NSCLCand 10 months in ES-NSCLC. Two-year survival was 30% in LS and8% in ES-NSCLC. Conclusion: Response-rates and survival after conventional-dose VIP-Echemotherapy are comparable to other published trials of combinationchemotherapy in NSCLC. Toxicity and mortality is acceptable in limited stage,but unacceptably high in extensive stage NSCLC. Although better response-rateswere achieved in the high-dose arm, they did not translate into improvedsurvival. Most stage IV NSCLC-patients will neither benefit from VIP-Econventional dose, nor from VIC-E high dose chemotherapy. Whether selectedLS-patients with partial or complete responses to VIP-E induction chemotherapycould benefit from dose intensification in an adjuvant or neo-adjuvant settingremains to be determined.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008209713568
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer (1997)
    Springer
    Annals of oncology 8 (1997), S. 49-56 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; hematopoietic growth-factor support ; high-dose chemotherapy ; peripheral blood stem cell transplantation ; small-cell lung cancer ; treatment toxicity and mortality
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: We conducted a phase I/II trial to assess the feasibilityand activity of VIP-E chemotherapy in small-cell lung cancer. End-points weretreatment-related morbidity and mortality, response to treatment, duration ofresponse, and survival. Patients and methods: Two cycles of combination chemotherapy followedby granulocyte colony-stimulating factor (G-CSF) were given at a dose ofetoposide (500 mg/m2), ifosfamide (4000mg/m2), cisplatin (50 mg/m2), and epirubicin(50 mg/m2) to 100 consecutive patients with SCLC. Thirtypatients (19 with LD, and 11 with ED SCLC) proceeded to VIC-E high-dosechemotherapy with autologous peripheral blood stem cell transplantation(PBSCT) at a cumulative dose of etoposide 1500 mg/m2,ifosfamide 12,000 mg/m2, carboplatin 750 mg/m2and epirubicin 150 mg/m2 (VIC-E). Surgical resection ofprimary tumor was attempted at the earliest feasible point. Thoracicirradiation was given after completion of chemotherapy. Results of conventional-dose VIP-E: 97 patients were evaluable forresponse. Objective response rate was 81% in LD-SCLC (33% CR,48% PR; excluding patients in surgical CR) and 77% in ED-SCLC(18% CR, 58% PR). Treatment mortality was 2%. Mediansurvival was 19 months in LD-SCLC and 6 months in ED-SCLC. Two-year survivalwas 36% in LD and 0% in ED SCLC. Results of high-dose VIC-E: All 30 patients improved on or maintainedprior responses. Four patients (13%) died of treatment-relatedcomplications. Median survival was 26 months in LD-SCLC and 8 months inED-SCLC. Two-year survival was 53% in LD and 9% in ED SCLC. Conclusion: VIP-E chemotherapy is an effective induction therapy forSCLC. Compared with traditional protocols such as ACO orcarboplatin/etoposide, response rates are slightly improved, while survivalis not different. In the LD SCLC subgroup, high-dose chemotherapy improvedresponse rates and survival, especially for patients in surgical CR prior tohigh-dose therapy. In ED SCLC, however, higher response-rates did nottranslate into improved survival. Selected LD-SCLC patients with good partialor complete remissions after prior therapy may benefit from HDC and PBSCT.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008232329498
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Lymphokine activated killer cells (1989)
    Springer
    Annals of hematology 59 (1989), S. 375-384 
    Details
    ISSN: 1432-0584
    Keywords: Lymphokine activated killer cells ; Interleukin-2
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Various subpopulations of human leukocytes may be induced by lymphokines to exert cytotoxic activity. In man major histocompatibility complex non-restricted tumor cell lysis by interleukin-2 (IL-2) induced peripheral blood lymphocytes is attributed mainly to natural killer cells. These T cell receptor negative large granular lymphocytes are called lymphokine activated killer (LAK) cells. In order to explore the potential of LAK cells in tumor therapy, several clinical studies have been conducted, using IL-2 alone or in combination with ex vivo IL-2-activated peripheral blood lymphocytes. Objective responses have reproducibly been achieved only in renal cell carcinoma and malignant melanoma and were associated with considerable toxicity. In view of restricted efficacy and increasing doubts as to whether LAK cells indeed account for the in vivo observed responses, more recent strategies focus on tumor antigen specific cytotoxic T cells or tumor infiltrating lymphocytes. Successful translation of this approach into clinical practice, however, may be dependend on some basic problems of tumor immunology to be solved which were thought to be by-passed by the LAK cell approach.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00321208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2 (1995)
    Springer
    Annals of hematology 70 (1995), S. 227-230 
    Details
    ISSN: 1432-0584
    Keywords: Interleukin-2 ; Acute myeloid leukemia ; Leukocytoclastic vasculitis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01700380
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (1997)
    Springer
    Annals of hematology 74 (1997), S. 73-77 
    Details
    ISSN: 1432-0584
    Keywords: Key words Autologous bone marrow transplantation ; Autologous peripheral blood stem cell transplantation ; High-dose chemotherapy ; Second and secondary primary neoplasms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  We treated 500 patients with high-dose chemotherapy (HDC) and autologous bone marrow (ABMT) or autologous peripheral blood stem cell transplantation (PBSCT). Treated conditions included leukemia, lymphomas, breast cancer, lung cancer, germ-cell carcinomas, and other solid tumors. In order to assess relapse of primary malignancy or occurrence of new neoplasms, routine screening after ABMT or PBPCT was performed at regular and close intervals. With a total follow-up of 1358 person-years and a median follow-up of 34 months (range 9–91), 10/500 (2%) patients developed second malignancies after PBSCT or ABMT; i.e., one new cancer occurred every 136 person-years. All malignancies were detected at routine follow-up examinations; and 7/10 diagnoses were made in an asymptomatic phase; 6/10 neoplasms were amenable to complete surgical resection, five of which remain in CR at a median of 23+ months after autotransplantation. We conclude that regular and close follow-up examination of patients after autologous hematopoietic stem cell transplantation may be beneficial, since successful treatment of second malignancies is possible in selected cases after early detection.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002770050260
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Untersuchung der DNS-abhängigen RNS-Polymerase aus menschlichen Leukocyten in einem einfachen zellfreien System (1973)
    Springer
    Journal of molecular medicine 51 (1973), S. 730-734 
    Details
    ISSN: 1432-1440
    Keywords: Leukocytes ; Leukemia ; RNA-polymerase ; RNA-metabolism ; Leukocyten ; Leukämie ; RNS-Polymerase ; RNS-Stoffwechsel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Lymphocyten und Leukocyten (Lymphocyten + Granulocyten) werden aus 10–40 ml heparinisiertem Venenblut isoliert, homogenisiert und 15 min bei 1000 g zentrifugiert. In dem aus Zellkernen und Kerntrümmern bestehenden Sediment lassen sich nach Resuspension ca. 70% der DNA-abhängigen RNS-Polymerase-Aktivität des Homogenats nachweisen. Die Reaktion ist von zugesetzter DNS und der Gegenwart aller vier Ribonucleosid-Triphosphate abhängig. Bei chronisch lymphatischer Leukämie, chronisch myeloischer Leukämie und Morbus Hodgkin findet sich unter diesen Bedingungen eine höhere spezifische Aktivität der DNS-abhängigen RNS-Polymerase als bei Normalpersonen.
    Notes: Summary Lymphocytes and leukocytes (lymphocytes + granulocytes), isolated from 10–40 ml of heparinized venous blood, are homogenized, and centrifuged for 15 min at 1000 g. The resuspended pellet, consisting of nuclei and nuclear debris, exhibits ca. 70% of the DNA-depenent RNA polymerase activity of the homogenate. The reaction depends on added DNA template and the presence of all four ribonucleoside triphosphates. In chronic lymphatic leukaemia, chronic myelocytic leukemia, and Hodgkin's disease, the activity of the DNA-dependent RNA polymerase is higher than in normal controls.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01468365
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    DNS-abhängige RNS-Polymerasen in menschlichen Leukocyten (1975)
    Springer
    Journal of molecular medicine 53 (1975), S. 311-316 
    Details
    ISSN: 1432-1440
    Keywords: DNA-dependent RNA polymerases ; leukemia ; prognostic factors ; DNS-abhängige RNS-Polymerasen ; Leukämie ; prognostische Kriterien
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die spezifischen Aktivitäten der DNS-abhängigen RNS-Polymerasen A und B wurden in von exogener Matrizen-DNS abhängiger Form bei verschiedenen Hämoblastosen bestimmt. Die Aktivitätsbestimmungen erfolgten in Kernhomogenaten isolierter mononucleärer oder segmentkerniger Leukocyten. Eine signifikante Erhöhung der Polymeraseaktivitäten A und B fand sich in den Kernhomogenaten mononucleärer Zellen bei akuter myeloischer Leukämie, während diese bei chronisch-myeloischer Leukämie (signifikant) und chronisch-lymphatischer Leukämie (nicht signifikant) erniedrigt waren. Unter cytostatischer Therapie findet sich eine Angleichung der Polymeraseaktivitäten an den Normbereich. Hiermit ergeben sich möglicherweise neue Kriterien zur Verlaufsbeurteilung von Hämoblastosen unter einer Polychemotherapie.
    Notes: Summary Specific Activities of DNA-dependent RNA polymerases A and B have been determined in nuclei from leukocytes in acute and chronic leukemia. Enzyme activities, dependent on exogenous DNA template, were determined in homogenates of nuclei from isolated mononuclear cells or from isolated granulocytes. Activities of polymerases A and B have been found significantly elevated in homogenates of nuclei from mononuclear cells in acute myelocytic leukemia, while they were found subnormal in corresponding cell fractions from chronic myelocytic leukemia and chronic lymphatic leukemia. During cytostatic treatment polymerase activities were approaching normal values. The prognostic relevance of these data for the course of human leukemia is discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01469057
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: A mature follow-up report (1999)
    Springer
    Annals of oncology 10 (1999), S. 605-607 
    Details
    ISSN: 1569-8041
    Keywords: hematopoietic growth-factors ; high-dose chemotherapy ; non-small-cell lung cancer ; peripheral blood stem-cell transplantation ; standard-dose chemotherapy ; treatment-related mortality
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: We conducted a phase I–II trial to assess the activity of standard-dose (SDC) and high-dose chemotherapy (HDC) with etoposide, ifosfamide, cis/carboplatin, and epirubicin (VIP-E, VIC-E) in 107 patients with limited-stage (LS, stage I–IIIB) and extensive stage (ES, stage IV) non-small-cell lung cancer (NSCLC). Patients and methods: Updated results of a previously published trial are presented. Results: Response rates and survival after VIP-E were comparable to those of other standard-dose combination chemotherapies in NSCLC. Treatment-related mortality (TRM) in SDC was 3% in LS-NSCLC, and 8% in ES-NSCLC. TRM was 4% in patients selected for HDC by response rate and performance score. Five-year survival in LS-NSCLC was 12% after SDC, and 18% after HDC; it was 0% for both treatment protocols in ES-NSCLC. Conclusions: The activity of VIP-E SDC and VIC-E HDC is not superior to that of established protocols in the treatment of NSCLC. In view of the toxicity and TRM associated with this protocol, less aggressive regimens should be preferred for most patients. Whether selected patients with chemosensitive disease could benefit from VIP-E SDC and/or VIC-E HDC in an adjuvant or neo-adjuvant setting could not be determined within the scope of this study.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1026462707001
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...